Stockscreener 앱 받기
9.65
1.03%
-0.10
시간 외 거래:
9.65
전일 마감가:
$9.75
열려 있는:
$9.65
하루 거래량:
4.37M
Relative Volume:
0.88
시가총액:
$4.72B
수익:
$4.45B
순이익/손실:
$205.00M
주가수익비율:
24.12
EPS:
0.4
순현금흐름:
$372.00M
1주 성능:
+1.47%
1개월 성능:
+5.46%
6개월 성능:
-23.84%
1년 성능:
-28.68%
1일 변동 폭
$9.51
$9.7892
1주일 범위
$9.32
$9.91
52주 변동 폭
$8.02
$18.80
엘란코 Stock (ELAN) Company Profile
명칭
Elanco Animal Health Inc
전화
877-352-6261
주소
2500 INNOVATION WAY, GREENFIELD
ELAN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ELAN
Elanco Animal Health Inc
|
9.65 | 4.72B | 4.45B | 205.00M | 372.00M | 0.40 |
|
ZTS
Zoetis Inc
|
158.06 | 68.50B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.38 | 47.71B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.63 | 46.12B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.39 | 18.78B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
298.70 | 13.40B | 2.76B | 1.11B | 898.10M | 22.77 |
엘란코 Stock (ELAN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-09 | 개시 | UBS | Buy |
| 2024-12-02 | 개시 | Leerink Partners | Market Perform |
| 2024-09-19 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-01-05 | 업그레이드 | Stifel | Hold → Buy |
| 2023-12-19 | 개시 | Jefferies | Buy |
| 2023-12-15 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-07 | 개시 | Exane BNP Paribas | Outperform |
| 2023-04-20 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2022-08-18 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-16 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-07-21 | 다운그레이드 | Goldman | Buy → Sell |
| 2022-07-12 | 개시 | Piper Sandler | Neutral |
| 2021-11-18 | 개시 | Morgan Stanley | Overweight |
| 2021-10-28 | 다운그레이드 | Stifel | Buy → Hold |
| 2021-08-05 | 재개 | Credit Suisse | Outperform |
| 2021-06-15 | 업그레이드 | Cleveland Research | Underperform → Neutral |
| 2021-05-11 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2021-05-11 | 업그레이드 | Gabelli & Co | Hold → Buy |
| 2021-04-15 | 개시 | Stifel | Buy |
| 2021-03-22 | 다운그레이드 | Gabelli & Co | Buy → Hold |
| 2021-02-26 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2020-12-09 | 다운그레이드 | Argus | Buy → Hold |
| 2020-11-09 | 다운그레이드 | Barclays | Overweight → Underweight |
| 2020-08-20 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-08-13 | 재개 | Credit Suisse | Neutral |
| 2020-08-04 | 재개 | Goldman | Buy |
| 2020-07-27 | 다운그레이드 | Cleveland Research | Neutral → Underperform |
| 2020-04-02 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-10 | 개시 | Raymond James | Mkt Perform |
| 2019-12-19 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-11-07 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2019-09-23 | 개시 | Barclays | Overweight |
| 2019-08-26 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-08-15 | 업그레이드 | UBS | Sell → Neutral |
| 2019-05-23 | 개시 | Guggenheim | Neutral |
| 2019-03-18 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-03-13 | 재개 | Morgan Stanley | Equal-Weight |
| 2019-02-12 | 개시 | William Blair | Mkt Perform |
| 2019-01-23 | 개시 | UBS | Sell |
| 2019-01-15 | 개시 | Argus | Buy |
| 2018-10-15 | 개시 | Morgan Stanley | Equal-Weight |
모두보기
엘란코 주식(ELAN)의 최신 뉴스
Elanco Animal Health Sells Xdemvy Royalties To Blackstone in $295 Million Deal - Benzinga
Commit To Buy Elanco Animal Health At $8, Earn 13.1% Using Options - Nasdaq
Elanco Sells Xdemvy Royalty, Milestone Rights to Blackstone Affiliates for $295 Million - marketscreener.com
Elanco Sells Royalty, Milestone Rights For Lotilaner In Human Health To Blackstone For $295 Mln Cash - Nasdaq
Elanco Sells Royalty and Milestone Rights for Lotilaner in Human Health to Blackstone; Accelerates Debt Paydown | ELAN Stock News - GuruFocus
Elanco Sells Royalty And Milestone Rights For Lotilaner In Human Health To Blackstone Accelerates Debt Paydown - marketscreener.com
Elanco Cuts Debt With $295M Blackstone Deal: Key Details on Leverage Target and XDEMVY Royalty Sale - Stock Titan
Analyzing Ratios: Elanco Animal Health Inc (ELAN)’s Financial Story Unveiled - DWinneX
Renaissance Technologies LLC Has $760,000 Position in Elanco Animal Health Incorporated (NYSE:ELAN) - Defense World
Cyromazine Market Deep Research Report with Forecast by 2032 | - openPR.com
Elanco Animal Health Inc [ELAN] Shares Fall Approximately -28.51% Over the Year - knoxdaily.com
US FDA approves Elanco's treatment for parasitic infections in dogs - AOL.com
Earnings Preview: Elanco Animal Health Incorporated (ELAN) Q1 Earnings Expected to Decline - Yahoo Finance
Companion Animal Specialty Drugs Market Is Booming So Rapidly | Elanco, Dechra, Zomedica - openPR.com
Mariner LLC Buys 24,901 Shares of Elanco Animal Health Incorporated (NYSE:ELAN) - Defense World
ELANCO ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Elanco Board Sued Over Safety, FDA Setbacks for Dog Itch Drug - Bloomberg Law News
Elanco Animal Health Inc (ELAN) Stock: A Comprehensive 52-Week Review - investchronicle.com
ELAN’s price-to-book ratio: An indicator of the company’s performance - uspostnews.com
A History of Outperforming Analyst Forecasts and Beating the Odds: Elanco Animal Health Inc (ELAN) - Sete News
Poultry Antibiotic Market Set to Witness Significant Growth - openPR.com
Press Release Distribution & PR Platform - ACCESS Newswire
Elanco Animal Health Incorporated (NYSE:ELAN) Shares Purchased by Envestnet Asset Management Inc. - Defense World
Russell Investments Group Ltd. Decreases Stake in Elanco Animal Health Incorporated (NYSE:ELAN) - Defense World
Elanco Animal Health Incorporated (NYSE:ELAN) Shares Sold by Wells Fargo & Company MN - Defense World
Elanco Animal Health Inc [ELAN] Records 200-Day SMA of $12.48 - knoxdaily.com
COSM Stock Sees Surge of Approximately 15.01% in Last Five Days - knoxdaily.com
A company insider recently bought 125,000 shares of Opko Health Inc [OPK]. Should You Buy? - knoxdaily.com
A company insider recently bought 2,735 shares of Evolent Health Inc [EVH]. Should You Buy? - knoxdaily.com
Elanco or Zoetis? Sarat Sethi reveals his preferred stock - Invezz
Oscar Health Inc [OSCR] Records 50-Day SMA of $13.76 - knoxdaily.com
Elanco vs Zoetis stock: Sarat Sethi picks a side - TradingView
Animal Parasiticides Market Projected To Witness Substantial - openPR.com
Q1 EPS Estimate for Elanco Animal Health Reduced by Analyst - Defense World
Protect Your Dog from Deadly Parvo VirusElanco Animal Health - iHeart
Is Elanco Animal Health Inc. (NYSE:ELAN) the Best Cheap Stock to Buy Under $10? - Yahoo Finance
Are Elanco Animal Health Inc (ELAN) shares a good deal now? - uspostnews.com
Elanco Animal Health Inc Inc. (ELAN) Price Performance: The Role of Share Buybacks and Stock Splits - investchronicle.com
Veterinary Healthcare Market Generated Opportunities, Future - openPR.com
Why Should We Buy Elanco Animal Health Inc (ELAN) Stock? - Marketing Sentinel
Animal Internal Parasiticide Market Attractive Growth Proposition Seen in 2025: Zoetis, Elanco Animal Health, Virbac - openPR.com
Elanco price target lowered to $13 from $16 at BofA - Yahoo Finance
Market Insight: Elanco Animal Health Inc (ELAN)’s Notable Gain, Closing at 8.48 - DWinneX
Elanco's Breakthrough Treatment for Deadly Canine Parvovirus Has Saved Thousands of Puppies, Reaffirms Commitment to Increasing the Availability of Canine Parvovirus Monoclonal Antibody for Second Ann - GuruFocus
Elanco's Breakthrough Treatment for Deadly Canine Parvovirus Has Saved Thousands of Puppies, Reaffirms Commitment to Increasing the Availability of Canine Parvovirus Monoclonal Antibody for Second Annual National Parvo Awareness Day - marketscreener.com
What Does the Market Think About Elanco Animal Health? - Benzinga
This trade activity should not be overlooked: Elanco Animal Health Inc (ELAN) - Sete News
Elanco (ELAN) Target Price Cut by BofA, Buy Rating Maintained | - GuruFocus
BofA Securities Adjusts Elanco Animal Health Price Target to $13 From $16, Maintains Buy Rating - marketscreener.com
Pet Pharmaceuticals Market to Witness a Pronounce Growth during - openPR.com
Pet Medication Market: Revenue Growth to Stoke Up in Next Couple - openPR.com
엘란코 (ELAN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):